The Long-Term Outcome of Medical Therapy for BPH

European Urology

Volumn 51, Issue 6, 2007, Pages 1522-1533

  Madersbacher, Stephan ^a   Marszalek, Martin ^a   Lackner, Jakob ^b   Berger, Peter ^c   Schatzl, Georg ^b  

^a DANUBE HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Benign prostatic hyperplasia; Efficacy; Long term outcome; Medical management; Natural history

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; PLANT EXTRACT; PUMPKIN EXTRACT; SABAL EXTRACT; SAW PALMETTO EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; STINGING NETTLE ROOT EXTRACT; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

ASTHENIA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; ECONOMIC ASPECT; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FLOW RATE; GYNECOMASTIA; HISTORY; HUMAN; INFORMATION; IRIS DISEASE; LIFE; LITERATURE; LONG TERM CARE; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REGISTER; REVIEW; RISK; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VASODILATATION;

ADRENERGIC ALPHA-ANTAGONISTS; CLINICAL TRIALS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLACEBO EFFECT; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 34247368970     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.03.034     Document Type: Review

References (95)

1. Marberger M., Harkaway R., and de la Rosette J. Optimizing the medical management of benign prostatic hyperplasia. Eur Urol 45 (2004) 411-419
2. Madersbacher S., Alivizatos G., Nordling J., Sanz C.R., Emberton M., and de la Rosette J.J. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46 (2004) 547-554
3. Schulman C.C. Long-term aspects of medical treatment of BPH. Eur Urol 40 Suppl 3 (2001) 8-12
4. Denis L., McConnell J., and Yoshida O. The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Denis L., Griffiths K., and Khoury S. (Eds). Fourth International Consultation on Benign Prostatic Hyperplasia (BPH) (1998), SCI, Paris 669-684
5. Teillac P., and Scarpa R.M. Economic issues in the treatment of BPH. Eur Urol Suppl 5 (2006) 1018-1024
6. Madersbacher S., Haidinger G., Struhal G., and for the Prostate Study Group of the Austrian Society of Urology. Management of lower urinary tract symptoms of elderly men in Austria. Eur Urol 39 (2001) 145-150
7. Berges R.R., and Pientka L. Management of the BPH syndrome in Germany: who is treated and how?. Eur Urol 36 Suppl 3 (1999) 21-27
8. Disantostefano R.L., Biddle A.K., and Lavelle J.P. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. BJU Int 97 (2006) 1007-1016
9. Jacobson S.J., Girman C.J., and Lieber M.M. Natural history of benign prostatic hyperplasia. Urology 58 Suppl 6A (2001) 5-16
10. Fitzpatrick J.M. The natural history of benign prostatic hyperplasia. BJU Int 97 Suppl 2 (2006) 3-6
11. Meigs J.B., Barry M.J., Giovannucci E., Rimm E.B., Stampfer M.J., and Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals follow-up study. J Urol 162 (1999) 376-382
12. Kok E.T., Bohnen A.M., Groeneveld F.P., Busschbach J.J., Blanker M.H., and Bosch J.L. Changes in disease specific and generic quality of life related to changes in lower urinary tract symptoms: the Krimpen study. J Urol 174 (2005) 1055-1058
13. Kok E.T., Bohnen A.M., Bosch J.L., Thomas S., and Groeneveld F.P. Patient's quality of life and coping style influence general practitioner's management in men with lower urinary tract symptoms: the Krimpen study. Qual Life Res 15 (2006) 1335-1343
14. Kok E.T., Groeneveld F.P., Gouweloos J., et al. Determinants of seeking of primary care for lower urinary tract symptoms: the Krimpen study in community-dwelling men. Eur Urol 50 (2006) 811-817
15. Mishra V., and Emberton M. To what extent do real life practice studies differ from randomized controlled trials in lower urinary tract symptoms/benign prostatic hyperplasia?. Curr Opin Urol 16 (2006) 1-4
16. Roehborn C.G. Definition of at-risk patients: baseline variables. BJU Int 97 Suppl 2 (2006) 7-11
17. Roberts R.O., Lieber M.M., Jacobsen D.J., Girman C.J., and Jacobsen S.J. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin Proc 80 (2005) 759-764
18. Anderson J.B., Roehborn C.G., Schalken J.A., and Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 39 (2001) 390-399
19. Emberton M. The hallmarks of BPH progression and risk factors. Eur Urol Suppl 2 8 (2003) 2-7
20. Fitzpatrick J.M., and Artibani W. Therapeutic strategies for managing BPH progression. Eur Urol Suppl 5 (2006) 997-1003
21. Madersbacher S., Haidinger G., Temml C., Schmidbauer C.P., and for the Prostate Study Group of the Austrian Society of Urology. Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men. Eur Urol 34 (1998) 136-141
22. Temml C., Broessner C., Schatzl G., Ponholzer A., Knoepp L., Madersbacher S., and Prostate Study Group of the Austrian Society of Urology. The natural history of lower urinary tract symptoms over 5 years. Eur Urol 43 (2003) 374-380
23. Thomas A.W., Cannon A., Bartlett E., Ellis-Jones J., and Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU Int 96 (2005) 1301-1306
24. Roberts R.O., Jacobsen S.J., Jacobsen D.J., Rhodes T., Girman C.J., and Lieber M.M. Longitudinal changes in peak urinary flow rates in a community-based cohort. J Urol 163 (2000) 107-113
25. Jacobsen S.J., Jacobsen D.J., Girman C.J., et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158 (1997) 481-487
26. Verhamme K.M., Dieleman J.P., van Wijk M.A., Bosch J.L., Stricker B.H., and Sturkenboom M.C. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 47 (2005) 494-498
27. McConnell J.D., Roehborn C.G., Bautista O.M., et al., Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
28. Roehborn C.G., and for the ALTESS Study Group. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 97 (2006) 734-741
29. Slawin K.M., Kattan M.W., Roehborn C.G., and Wilson T. Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. Urology 67 (2006) 84-88
30. Schagen van Leeuwen J.H., Castro R., Busse M., and Bemelmans B.L.H. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 50 (2006) 440-453
31. Roehrborn C.G. Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions. Urology 59 (2002) 811-815
32. Nickel J.C., and for the Canadian PROSPECT Study Group. Placebo therapy of benign prostatic hyperplasia: a 25 months study. Br J Urol 81 (1998) 383-387
33. Emberton M. Patient-led management of BPH: from watchful waiting to self-management of LUTS. Eur Urol Suppl 5 (2006) 704-709
34. Bent S., Kane C., Shinohara K., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 354 (2006) 557-566
35. Schneider T., and Rübben H. Extract of stinging nettle roots (Bazoton-uno) in long-term treatment of benign prostatic syndrome (BPS). Results of a randomized, double blind, placebo-controlled multicentre study after 12 months. Urologe [A] 43 (2004) 302-306
36. Bach D., and und der interdisziplinärer Arbeitskreis Prostata. Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Urologe [B] 40 (2000) 437-443
37. Sökeland J., and Albrecht J. Combined Sabal and Urtica extract vs. finasteride in BPH (Alken stage I-II). Urologe [A] 36 (1997) 327-333
38. Debruyne F., Koch G., Boyle P., et al. Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 41 (2002) 497-507
39. Dreikorn K., Berges R., Pientka L., and Jonas U. Phytotherapie bei BPH. Aktuelle evidenzbasierte Bewertung. Urologe [A] 41 (2002) 447-451
40. Madersbacher S., Schatzl G., Broessner C., and Dreikorn K. Phytotherapy for BPS: which products can still be prescribed. Urologe [A] 44 (2005) 513-520
41. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter I. Diagnosis and treatment recommendation. J Urol 170 (2003) 530-547
42. Berges R., Dreikorn K., Höfner K., et al. Guidelines of German urologists on therapy of benign prostatic syndrome. Urologe [A] 42 (2003) 722-738
43. Boyle P., Robertson C., Lowe F., and Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93 (2004) 751-756
44. Ishani A., MacDonald R., Nelson D., Rutks I., and Wilt T.J. Pyogenum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 109 (2000) 654-664
45. Roehborn C.G. Editorial comment. Comparison of Permixon with tamsulosin. Eur Urol 41 (2002) 497-507
46. Djavan B., Chapple C., Milani S., and Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64 (2004) 1081-1088
47. Roehrborn C.G., Oesterling J.E., Auerbach S., et al., for the Hycat Investigator Group. The Hytrin community assessment trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 47 (1996) 159-168
48. Lepor H., Williford W.O., Barry M.J., et al., Veterans Affairs Cooperative Studies, benign prostatic hyperplasia study group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335 (1996) 533-539
49. Lepor H., and for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double blind extension of phase III trial. Urology 51 (1998) 901-906
50. Kirby R.S., Roehrborn C., Boyle P., et al., for the PREDICT Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia. The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61 (2003) 119-126
51. Lukacs B., Grange J.C., McCarthy C., Comet D., and the BPH Group in General Practice. Clinical uroselectivity: a 3-year follow-up in general practice. Eur Urol 33 Suppl 2 (1998) 28-33
52. Schulman C.C., Cortvriend J., Jonas U., Lock T.M., Vaage S., Speakman M.J., and on the behalf of the European Tamsulosin Study Group. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicentre, open-label study. Eur Urol 36 (1999) 609-620
53. Elhilali M., Emberton M., Matzkin H., et al., for the ALF-ONE study group. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in "real-life" practice. BJU Int 97 (2005) 513-519
54. Narayan P., and Lepor H. Long-term, open label, phase III mullticenter study of tamsulosin in benign prostatic hyperplasia. Urology 57 (2001) 466-470
55. de la Rosette J.J.M.C.H., Kortmann B.B.M., Rossi C., Sonke G.S., Floratos D.L., and Kiemeney L.A.L.M. Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J Urol 167 (2002) 1734-1739
56. Andersen J.T., Ekman P., Wolf H., et al. Can finasteride reverse the process of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH study group. Urology 46 (1995) 631-637
57. Nickel J.C., Fradet Y., Boake R.C., et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 155 (1996) 1251-1259
58. Lowe F.C., McConnell J.D., Hudson P.B., et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 61 (2003) 791-796
59. Marberger M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicentre study. PROWESS Study Group. Urology 51 (1998) 677-686
60. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338 (1998) 557-563
61. Roehborn C.G., Boyle P., Nickel J.C., Hoefner K., Andriole G., ARIA3001, and ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
62. Roehborn C., and Heaton J.P.W. Medical management for BPH: the role of combination therapy. Eur Urol Suppl 5 (2006) 716-721
63. Crawford E.D., Wilson S.S., McConnell J.D., et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175 (2006) 1422-1427
64. Kim C.I., Chang H.S., Kim B.K., and Park C.H. Long-term results of medical treatment in benign prostatic hyperplasia. Urology 68 (2006) 1015-1019
65. Barkin J., Guimaraes M., Jacobi G., Pushkar D., Taylor S., van Vierssen Trip O.B., and on behalf of the SMART-1 Investigator Group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 44 (2003) 461-466
66. Zlotta A.R., Teillac P., Raynaud J.P., and Schulman C.C. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride. Eur Urol 48 (2005) 269-276
67. Montorsi F., and Moncada I. Safety and tolerability of treatment for BPH. Eur Urol Suppl 5 (2006) 1004-1012
68. Vallancien G., Emberton M., Harving N., van Moorselaar R.F., and Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 169 (2003) 2257-2261
69. Jeroen R., van Moorselaar A., Hartung R., et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 95 (2005) 603-608
70. Auerbach S.M., Gittelman M., Mazzu A., Cihon F., Sundaresan P., and White W.B. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 64 (2004) 998-1003
71. Giuliano F., Kaplan S.A., Cabanis M.J., and Astruc B. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 67 (2006) 1199-1204
72. Chang D.F., and Campbell J.R. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31 (2005) 664-673
73. Lawrentschuk N., and Bylsma G.W. Intraoperative "floppy iris" syndrome and its relationship to tamsulosin: a urologist's guide. BJU Int 97 (2006) 2-4
74. Akduman B., and Crawford E.D. The PCPT: new findings, new insights, and clinical implications for the prevention of prostate cancer. Eur Urol Suppl 5 (2006) 634-639
75. Roehrborn C.G., Lee M., Meehan A., Waldstreicher J., and PLESS Study Group. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology 62 (2003) 894-899
76. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 169 (2003) 1520-1525
77. Souverein P.C., Erkens J.A., de la Rosette J.J.M.C.H., Leufkens H.G.M., and Herings R.M. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur Urol 43 (2003) 528-534
78. Fitzpatrick J.M., and Kirby R.S. Management of acute urinary retention. BJU Int 97 Suppl 2 (2006) 16-20
79. McNeill S.A., Hargreave T.B., Roehborn C.G., and Alfaur study group. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 65 (2005) 83-89
80. Shah T., Palit V., Biyani S., Elmasry Y., Puri R., and Flanigan G.M. Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. Eur Urol 42 (2002) 329-332
81. Roehborn C.G., Bruskewitz R., Nickel J.C., et al., for the Proscar Long-Term Efficacy and Safety Study Group. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 171 (2004) 1194-1198
82. Van Exel N.J., Koopmanschap M.A., McDonnell J., Chapple C.R., Berges R., and Rutten F.F. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol 49 (2006) 92-102
83. Hutchison A., Farmer R., Verhamme K., Berges R., and Navarrete R.V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 51 (2007) 207-216
84. Verhamme K.M., Dieleman J.P., Bleumink G.S., Bosch J.L., Stricker B.M., and Sturkenboom M.C. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 44 (2003) 539-545
85. McDonald H., Hux M., Brisson M., Bernard L., and Nickel J.C. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol 11 (2004) 2327-2340
86. Florentinus S.R., Souverein P.C., Griens F.A.M.G., Groenewegen P.P., Leufkens H.G.M., and Heerdink E.R. Linking community pharmacy dispensing data to prescribing data of general practitioners. BMC Med Inform Decis Mak 6 (2006) 18-23
87. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
88. Flanigan R.C., Reda D.J., Wasson J.H., Anderson R.J., Abdellatif M., and Bruskewitz R.C. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia. A department of Veterans Affairs Cooperative Study. J Urol 160 (1998) 12-17
89. Debruyne F., Barkin J., van Erps P., Reis M., Tammela T.L., Roehrborn C., on behalf of the ARIA3001, and ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488-495
90. Madersbacher S., Klingler C.H., Schatzl G., Stullnig T., Schmidbauer C.P., and Marberger M. Age related urodynamic changes of patients with benign prostatic hyperplasia. J Urol 156 (1996) 1662-1667
91. Vela-Navarrete R., Gonzalez-Enguita C., Garcia-Cardoso J.V., Manzarbeitia F., Sarasa-Corral J.L., and Granizo J.J. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU Int 96 (2005) 1045-1048
92. Debruyne F.M. Medical management of BPH: the debate continues. Eur Urol 50 (2006) 416-417
93. Roehborn C.G. Drug treatment for LUTS and BPH: new is not always better. Eur Urol 49 (2006) 5-7
94. Colli E., Rigatti P., Montorsi F., et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 49 (2006) 82-86
95. Untergasser G., Madersbacher S., and Berger P. Benign prostatic hyperplasia: age-related remodelling. Exp Gerontol 40 (2005) 121-128